Johnson & Johnson (Janssen)
#1 pharma company by 2024 Rx revenue ($53.5B). Janssen pharmaceutical division focuses on immunology, oncology, and neuroscience.
Services Offered
Our Take
J&J's pharma arm Janssen dethroned Pfizer as #1 in 2024 Rx sales. They make critical drugs for autoimmune conditions (Stelara, Tremfya) and cancer. Their CarePath program can cut costs from thousands to near-zero for qualifying patients. Always ask about CarePath if you're prescribed a Janssen drug.
Pros
- ✓#1 pharma by Rx revenue (2024)
- ✓Strong patient support (CarePath)
- ✓Innovative biologics
- ✓Diversified portfolio
Cons
- ✗Complex specialty drugs
- ✗Requires specialty pharmacies for some
- ✗Insurance navigation can be tricky
Pricing Details
Janssen CarePath provides savings programs and patient assistance for eligible individuals.
Best For
- • Autoimmune conditions
- • Cancer treatment
- • Mental health medications
Coverage
- 📍 Global
Accreditations
- ✓FDA approved
Trust Indicators
Years in Business
138+
Last verified: December 21, 2024
⚠️ Important
Always verify pricing and details directly with the provider. Prices shown are estimates based on our research as of December 2024 and may have changed.
This information is for educational purposes only and does not constitute medical advice. Consult with qualified healthcare professionals before making medical decisions.
We may earn a commission if you use our links, but this does not affect our editorial opinions or the information presented.
Opens in new window • direct link